Related Experiment Video
Updated: Aug 13, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis
Achille Marino1, Luca Marelli2, Paolo Nucci3
1Pediatric Rheumatology, ASST G.Pini-CTO, Milan, Italy.
Aim:
To describe the efficacy and safety of subcutaneous tocilizumab (SC-TCZ) in a cohort of juvenile idiopathic arthritis (JIA) patients with refractory uveitis.
Methods:
Retrospective observational monocentric study including patients with JIA-associated uveitis treated with SC-TCZ.
Results:
Thirteen patients were enrolled. The rate of uveitis flare/year per each patient was 1.6 ± 2.0 on the last bDMARDs before SC-TCZ, while it decreased to 0.4 ± 0.7 on SC-TCZ. Nine out of thirteen patients (69%) required the introduction of SC-TCZ only for active uveitis at baseline. Among these patients, five (56%) achieved complete treatment response. No uveitis relapses were observed in patients (4/13, 31%) requiring the introduction of SC-TCZ for active arthritis during follow-up (30.48 ± 21.6 months). Overall, SC-TCZ was safe, and no side effects were observed during the treatment.
Conclusion:
SC-TCZ can be effective and safe in patients with JIA and uveitis recalcitrant to several bDMARDs.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

